What is the best way to deliver subcutaneous insulin to infants, children, and young people with type 1 diabetes mellitus? by Blair, J. C. et al.
UNCERTAINTIES PAGE
What is the best way to deliver subcutaneous insulin
to infants, children, and young people with type 1
diabetes mellitus?
J C Blair consultant endocrinologist 1, M Peak director of research 2, J W Gregory professor in
paediatric endocrinology 3
1Department of Endocrinology, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK; 2Department of Research and
Development, Alder Hey Children’s NHS Foundation Trust ; 3Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK
This is one of a series of occasional articles that highlight areas of
practice where management lacks convincing supporting evidence. The
series adviser is David Tovey, editor in chief, theCochrane Library. This
paper is based on a research priority identified and commissioned by
the National Institute for Health Research’s Health Technology
Assessment programme on an important clinical uncertainty. To suggest
a topic for this series, please email us at uncertainties@bmj.com.
Type 1 diabetes is a common disease of childhood affecting
approximately 23 000 children and young people in England.1
The daily management of type 1 diabetes is burdensome.
However, over a lifetime, long term complications are likely to
have the greatest adverse impact on quality of life, and pose a
significant economic burden to society and the NHS. The
prevalence of long term complications is lowest in those with
good glycaemic control using intensive insulin regimes in the
form of insulin pump therapy or multiple daily injections.2 A
recent review of paediatric diabetes services in the United
Kingdom reported that 94% of centres offered intensive insulin
regimes, and 78% offer treatment with insulin pump therapy.3
Despite the widespread availability of insulin pump therapy,
data published by the National Diabetes Information Service in
2010 reported that only 1812 people aged less than 18 years
were treated with insulin pumps in England.4
The National Institute for Health and Clinical Excellence
recommends insulin pump therapy as a treatment option from
diagnosis of type 1 diabetes for patients aged less than 12 years
and for those aged 12 years and above with inadequate
glycaemic control on multiple daily injections or disabling
hypoglycaemia,5 with the intention of optimising glycaemic
control and quality of life. However, the authors of this guideline
recognise that the evidence supporting their recommendations
is poor. The additional cost of insulin pump therapy is estimated
to be £1700 (€1950; $2770) per annum.6At present there is little
robust evidence that this additional investment significantly
improves glycaemic control, reduces the prevalence of long
term complications, or improves quality of life in the paediatric
population. We consider the strengths and weaknesses of the
key evidence informing national guidelines and clinical practice.
What is the evidence of the uncertainty?
We searched the Cochrane Library, the Health Technology
Assessment library, andMEDLINE, using the terms andMeSH
headings: diabetes, continuous subcutaneous injection, insulin
pump, multiple daily injections, MDI, child, infant, adolescent.
A large number of studies were found. These have been critically
appraised in two meta-analyses7 8 and a Health Technology
Assessment6 review.
A Cochrane review7 reported data from seven paediatric
randomised controlled trials collectively studying 210
individuals.9-15 Studies are summarised in the table⇓. Observation
periods ranged from six days to two years. It was estimated that
in those treated with insulin pump therapy, HbA1c was 0.2
percentage points lower (95% confidence interval 0.40% to
0.03% (p=0.02)) compared with those treated with multiple
daily injections. Differences in study methodology precluded
a meta-analysis of hypoglycaemic events.
A recent meta-analysis8 reported data from six paediatric
randomised controlled trials10 14-18 collectively studying 165
people observed for 4 to 12 months (table⇓). The authors also
reported a favourable effect of insulin pump therapy on HbA1c
of 0.2 percentage points (95% confidence interval 0.40% to
0.10% (P<0.001)). Insulin dose was significantly lower in
patients treated with insulin pump therapy (0.22 units/kg/day,
95% confidence interval 0.31 to 0.14 (P<0.001)). There was no
statistically significant difference in the rate of severe
hypoglycaemic events or diabetic ketoacidosis.
Correspondence to: J Blair jo.blair@alderhey.nhs.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5221 doi: 10.1136/bmj.d5221 Page 1 of 4
Practice
PRACTICE
A meta-analysis of quality of life was not undertaken in either
study because of methodological differences between
randomised controlled trials. Three studies9 13 17 used the
Diabetes Treatment Satisfaction Questionnaire and all reported
greater satisfaction in those treated with insulin pump therapy.
The Diabetes Quality of Life Questionnaire for the Young was
used in three studies.9 10 17 There was no difference in outcomes
between treatment groups in two studies,10 17whereas one group
reported greater satisfaction in patients treated with insulin pump
therapy but no difference in measures of worry or impact.9
Although there is a trend for these meta-analyses to report a
favourable effect of insulin pump therapy on glycaemic control,
it is difficult to be certain of the importance of this modest
reduction in HbA1c on long term clinical outcomes, despite the
fact that it is generally accepted that differences in HbA1c of
0.5% or greater are clinically significant.
There are a number of methodological weaknesses in most
studies reported to date. Studies recruiting patients with poor
glycaemic control and randomising to continued multiple daily
injections or a switch to insulin pump therapy may show an
improvement with insulin pump therapy, for two reasons:
(1) Selection bias of participants with a preference for insulin
pump therapy: patients on established multiple daily
injections with good glycaemic control who are satisfied
with their current therapy are less likely to be approached
or agree to participate in these studies.
(2) Increased contact with diabetes healthcare professionals:
at the start of insulin pump therapy patients receive an
intensive period of education.
The observation periods in many studies are likely to be too
brief for patients to acquire the skills required to use insulin
pumps to their full potential,10 11 14 17 in others too brief to show
patient fatigue in the use of this intensive therapy,9 15 16 and no
study has been of sufficient duration to evaluate the impact of
insulin pump therapy on long term complications. The number
of patients recruited to each study is small, between 16 and 72
per study.
To date, there are only two multicentre studies,12 13 one
two-centre study,18 and three 9 14 17 of the ten randomised
controlled trials are single-centre. Also, to date no randomised
controlled study has been delivered in the UK, where healthcare
services differ from those in which insulin pump therapy and
multiple daily injections have previously been studied. No study
has investigated the health economics of insulin pump therapy.
Finally, most studies do not use “best possible multiple daily
injections” as the comparator to insulin pump therapy. Insulin
analogues have been reported to improve glycaemic control in
paediatric practice19 though only one study uses analogue insulin
for the treatment of all patients using multiple daily injections.10
The Health Technology Assessment review6 reported evidence
from a wider range of sources, including seven randomised
controlled trials9 10 14-18 and 28 observational studies reporting
data from 158 patients observed from 7 to 12 months and 1792
patients observed from six months to five years respectively.
Representations from patients and industry were also included.
The authors concluded that there was a modest reduction in
HbA1c in patients treated with insulin pump therapy, but a more
important reduction in hypoglycaemic events. The authors
reported that improvements in glycaemic control were greater
in observational studies than in randomised controlled trials and
recognised that these studies are more prone to bias. However,
they also commented that observational studies may be more
representative of clinical practice. The authors highlighted a
number of benefits in quality of life including a reduction in the
fear of hypoglycaemia, greater flexibility, and increased ability
to cope with unexpected exercise and food.
Is ongoing research likely to provide
relevant evidence?
We found only two studies in a search of the World Health
Organization’s International Clinical Trials Research Platform
Portal (Australia New Zealand Trials Registry, clinicaltrials.
gov, ISRCTN register) using the terms “children” AND “type
1 diabetes” AND (“pumps” OR “subcutaneous”).
ACTRN12610000605099 will recruit 110 young people aged
nine to 15.5 years with type 1 diabetes to investigate the effect
of insulin pump therapy compared to multiple daily injections
of insulin on parental report of behaviour four months after
randomisation.
ISRCTN29255275 is led by the authors of this paper. The study
will recruit 316 children and young people aged six months to
15 years with newly diagnosed type 1 diabetes to investigate
the effect of insulin pump therapy compared to multiple daily
injections on glycaemic control, as measured by HbA1c, 12
months after diagnosis. Secondary outcomes include measures
of quality of life and an economic analysis extrapolated to
estimate lifetime costs and benefits.
What should we do in the light of the
uncertainty?
To date there are insufficient data to recommend the use of
insulin pump therapy rather than multiple daily injections as
treatment of first choice to children with type 1 diabetes. Until
more robust data are available, treatment with insulin pump
therapy should be reserved for those in whom glycaemic control
is inadequate, or for those with disabling hypoglycaemia. There
is some evidence that quality of life and satisfaction may be
improved during insulin pump therapy, but our ability to
measure this in routine clinical practice is probably inadequate
(although individual and family preference should not be
overlooked). Finally, it is important to recognise that the long
term benefits of insulin pump therapy are unproven and the
benefits and costs of therapy to the individual should be critically
appraised on a regular basis.
JCB developed the ideas for this paper with MP, and JWG searched
and appraised the literature, drafted and revised the manuscript and
gave final approval of the article. JCB is chief investigator of study
ISRCTN29255275. MP has contributed to the development of this
manuscript through searching and appraisal of literature and is a
co-applicant on study ISRCTN29255275. He has also contributed to
the drafting, editing, revision and approval of this article. JWG has
contributed to the ideas behind this manuscript and is a co-applicant
on study ISRCTN29255275. He has also contributed to the drafting,
revision and approval of this article. JCB is guarantor.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: study ISRCTN29255275
is led by the authors of this paper. It is funded by the Health Technology
Assessment programme of the National Institute for Health Research.
The study team and Roche Diagnostics have agreed that where insulin
pumps and consumables supplied by Roche Diagnostics are used the
cost will be discounted by 25%. JCB has received payment for
consultancy work and speaker’s fees from Novo Nordisk, and is a chief
investigator for a study funded by Novo Nordisk. Novo Nordisk and
Pfizer have sponsored a nurse salary within the Department of
Endocrinology at Alder Hey Children’s NHS Foundation Trust. JCB and
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5221 doi: 10.1136/bmj.d5221 Page 2 of 4
PRACTICE
Recommendation for further research
Population: infants aged more than 6 months, children, and young people
Intervention and comparison: insulin pump therapy compared with multiple daily injections
Outcome: glycaemic control, frequency of severe hypoglycaemia and diabetic ketoacidosis, quality of life, growth and
weight gain, insulin requirements, and cost effectiveness based on the incremental cost per quality of adjusted life
years (QALY) gained
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Table
Table 1| Clinical characteristics and between group analyses in patients treated with insulin pump therapy and multiple daily injections
studied in randomised controlled trials. Values are mean (standard deviation) unless stated otherwise
Difference in outcomes IPT v MDI at
study completion
Baseline characteristics of patientsObservation
periodStudy design Duration TID (years)HbA1c (%)Age (years)N
No difference in HbA1c or severe
hypoglycaemia. Treatment satisfaction 32.0
(6.5) v 21.8 (3.7), P<0.05
Not reportedIPT 8.6 (0.8)
MDI 8.5 (1.4)
Median 14.2 (range
14.1–17.5)
166 months each
arm
Crossover RCT9
HbA1c (%): 7.2 v 8.1, P<0.05. Insulin doses
(units/kg/day): 0.9 v 1.2, P<0.003. No
difference in quality of life
IPT 6.8 (3.8)
MDI 5.6 (4.0)
IPT 8.2 (1.1)
MDI 8.1 (1.2)
IPT 12.5 (3.2)
MDI 13.0 (2.9)
3216 weeksParallel RCT10
No significant difference in blood glucose
(mean of seven samples/day) or 24 hour
glycosuria
Not reportedIPT 10.5 (2.9)
MDI 10.7 (1.1)
IPT 13.3 (4.0)
MDI 12.9 (2.4)
166 daysParallel RCT11
No significant difference in quality of life or
glycaemic control
IPT 5.6 (3.3)
MDI 4.7 (2.9)
IPT 8.3 (0.8)
MDI 8.4 (1.1)
IPT 10.0 (3.0)
MDI 10.0 (3.7)
38IPT 10.5 months;
MDI 3.5 months;
then IPT 7
months
Parallel RCT12
No difference in HbA1c or severe
hypoglycaemia. Insulin doses (units/kg/day):
0.7 v 1.1, P=0.001. Treatment satisfaction:
33.1 (0.9) v 27.5 (2.0), P<0.001
IPT 12.2 (2.0)
MDI 10.4 (1.7) (days)
IPT 8.2 (0.4)
MDI 8.4 (0.5)
IPT 11.8 (4.9)
MDI 12.3 (4.5)
722 yearsParallel RCT13
No significant difference in HbA1c, severe
hypoglycaemia, DKA, or quality of life.
Treatment satisfaction: 30.6 (3.7) v 21.9
(3.8), P<0.001
Median 6.0 (2.5 to
11.0)
Median 8.9 (6.1 to
10.1)
Median 11.9 (9.3 to
13.3)
233.5 months each
arm
Crossover RCT14
No difference in HbA1c or severe
hypoglycaemia
IPT 1.8 (0.6)
MDI 1.8 (0.6)
IPT 9.0 (0.6)
MDI 9.0 (0.6)
IPT 3.8 (0.8)
MDI 3.7 (0.7)
426 monthsParallel RCT15
No difference in HbA1c or severe
hypoglycaemia. Fathers of subjects reported
greater improvement in quality of life with
IPT v MDI, P=0.03
IPT 1.2 (0.3)
MDI 1.6 (0.3)
IPT 7.4 (0.5)
MDI 7.6 (0.3)
IPT 3.9 (0.4)
MDI 3.8 (0.4)
2624 weeksParallel RCT16
No difference in HbA1c, number of
hypoglycaemic events. Fasting glucose
within target (%): 27 (20) v 17 (16), P=0.01.
AUC (mg/dL), 24 hr: 377 (377) v 638 (727),
P=0.04.
Hyperglycaemic events, 24 hour: 3.4 (1.2) v
2.9 (1.0), P=0.04
Arm A 5.3 (1.9)
Arm B 6.3 (2.6)
Arm A 8.0 (1.1)
Arm B 8.3 (0.7)
Arm A 11.9 (1.4)
Arm B 11.9 (1.5)
233.5 months each
arm
Crossover RCT17
No difference in HbA1c, quality of life,
episodes of severe hypoglycaemia or DKA
1.4 (0.6)8.0 (0.8)3.6 (1.0)2252 weeksParallel RCT18
TID: type 1 diabetes; RCT: randomised controlled trial; IPT: insulin pump therapy; MDI: multiple daily injections; DKA: diabetic ketoacidosis; CGM: continuous
glucose monitoring; AUC: area under the curve.
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